文献速递肿瘤 PET/CT放射性药物与辐射防护

[18F]Florastamin作为前列腺癌正电子发射断层显像剂的多剂量临床试验

A microdose clinical trial to evaluate [18F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-05-26

本研究纳入5名健康对照和10例前列腺癌患者,注射370 MBq [18F]Florastamin后于0、10、30、70、120分钟行PET显像,评估生物分布与内照射剂量。原发肿瘤SUVmax随时间升高,肿瘤/本底比值良好,转移灶表现相似;肾脏吸收剂量最高(0.062 ± 0.015 mGy/MBq),有效剂量1.81 mSv,未见相关不良事件。

要点

  • 原发肿瘤SUVmax随时间升高,肿瘤/本底比值良好。
  • 肾脏吸收剂量最高(0.062 ± 0.015 mGy/MBq),有效剂量1.81 mSv。
  • 未见与[18F]Florastamin相关的不良事件。

核心结论

  • 研究识别出新型靶向前列腺特异性膜抗原(PSMA)的PET配体[18F]Florastamin用于前列腺癌显像,原发肿瘤和转移灶均显示高SUVmax和较高肿瘤/本底比值,提示其检测肿瘤敏感性高且无不良事件。

研究设计与样本

  • 微剂量临床试验纳入5名健康对照和10例前列腺癌患者,注射370 MBq [18F]Florastamin后于0、10、30、70、120分钟行PET显像,评估原发肿瘤SUVmax、正常器官SUVmean及驻留时间,并用OLINDA/EXM软件计算内照射剂量。

主要发现

  • 原发肿瘤SUVmax随时间升高,肿瘤/本底比值亦随时间改善。
  • 多发淋巴结和骨转移灶表现与原发肿瘤SUVmax相似。
  • 1例患者经[18F]Florastamin PET发现其他模态未观察到的小淋巴结转移,并经组织学确认。
  • 吸收剂量最高为肾脏(0.062 ± 0.015 mGy/MBq),其次为膀胱(0.032 ± 0.013 mGy/MBq)、肝脏(0.022 ± 0.006 mGy/MBq)和唾液腺(0.018 ± 0.006 mGy/MBq)。
  • 注射370 MBq [18F]Florastamin的有效剂量为1.81 mSv,未见相关不良事件。

关键数值与推荐

  • 原发肿瘤SUVmax随时间升高,肿瘤/本底比值随时间改善。
  • 肾脏吸收剂量0.062 ± 0.015 mGy/MBq,膀胱0.032 ± 0.013 mGy/MBq,肝脏0.022 ± 0.006 mGy/MBq,唾液腺0.018 ± 0.006 mGy/MBq。
  • 注射370 MBq [18F]Florastamin的有效剂量为1.81 mSv。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the biodistribution of [18F]Florastamin, a novel 18F-labelled positron emission tomography (PET) tracer for prostate-specific membrane antigen (PSMA) for the diagnosis of prostate cancer. METHODS: PET was performed for five healthy controls and 10 patients with prostate cancer at 0, 10, 30, 70, and 120 mins after injecting 370 MBq of [18F]Florastamin. The maximum standardised uptake value (SUVmax) was evaluated in the primary tumour. The mean SUVmax (SUVmean) was evaluated in normal organs. Furthermore, the residence time was evaluated by assessing radioactivity in each organ. The internal radiation dosimetry was calculated using the OLINDA/EXM software. RESULTS: The SUVmax in primary tumours increased with time. A favourable tumour to background ratio was also observed over time. Multiple lymph nodes and bone metastases were also evaluated and showed a similar pattern to SUVmax in the primary tumour. In one patient, a tiny lymph node metastasis was identified using [18F]Florastamin PET, which was not observed using other modalities, and was histologically confirmed. The highest absorbed dose was observed in the kidney (0.062 ± 0.015 mGy/MBq), followed by the bladder (0.032 ± 0.013 mGy/MBq), liver (0.022 ± 0.006 mGy/MBq), and salivary gland (0.018 ± 0.006 mGy/MBq). The effective dose with a 370 MBq injection of [18F]Florastamin was 1.81 mSv. No adverse events related to [18F]Florastamin were reported. CONCLUSION: We identified a novel PSMA-targeted PET ligand, [18F]Florastamin, for imaging prostate cancer. [18F]Florastamin showed a high SUVmax and relatively high tumour to background ratio in both primary tumour and metastatic lesions, which suggests its high sensitivity to detect tumours without any adverse events. TRIAL REGISTRATION: KCT0003924 registered at https://cris.nih.go.kr/ .

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lee I, Lim I, Byun BH, et al. A microdose clinical trial to evaluate [18F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 32458006. doi:10.1007/s00259-020-04883-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。